TrialJournal of translational medicine2010

A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899.

Robert S DiPaola et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.